Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3929]
News [11457]
Articles [47]
Editorials [10]
Conferences [201]
elearning [4]
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib
Dr Giorgio Scagliotti - University of Turin, Turin, Italy
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC...
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016
Firstline pembrolizumab plus chemo improves NSCLC outcomes
Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Firstline pembrolizumab plus chemo improves NSCLC outcomes ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016
KRAS in the clinic and conference
Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
KRAS in the clinic and conference ( Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
9 Oct 2016
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI...
Dr Arndt Stahler - University of Munich, Munich, Germany
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1) ( Dr Arndt Stahler - University of Munich, Munich, Germany )
9 Oct 2016
Thousands of melanoma patients in Europe have no access to new drugs
Prof Lidija Kandolf Sekulovic - Military Medical Academy, Belgrade, Serbia
Thousands of melanoma patients in Europe have no access to new drugs ( Prof Lidija Kandolf Sekulovic - Military Medical Academy, Belgrade, Serbia )
9 Oct 2016
Phase I results of a novel FGFR inhibitor
Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland
Phase I results of a novel FGFR inhibitor ( Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland )
9 Oct 2016
Firstline pembrolizumab for metastatic urothelial cancer
Dr Arjun Balar - NYU Langone Medical Center, New York, USA
Firstline pembrolizumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )
9 Oct 2016
Ribociclib improves progression-free survival in advanced breast cancer
Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center...
Ribociclib improves progression-free survival in advanced breast cancer ( Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston, US )
8 Oct 2016
Niraparib significantly improves outcomes for ovarian cancer patients
Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark
Niraparib significantly improves outcomes for ovarian cancer patients ( Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark )
8 Oct 2016
Ipilimumab as adjuvant therapy improves OS in high risk melanoma
Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France
Ipilimumab as adjuvant therapy improves OS in high risk melanoma ( Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France )
8 Oct 2016
Cancer care in Wales - challenges and opportunities
Prof Malcolm Mason - Cardiff University, Cardiff, UK
Cancer care in Wales - challenges and opportunities ( Prof Malcolm Mason - Cardiff University, Cardiff, UK )
6 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation